Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Frequently asked questions
What sector does Estrella Immunopharma Inc. (ESLAW) operate in?
Estrella Immunopharma Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Estrella Immunopharma Inc. (ESLAW) current stock price?
As of the latest data, Estrella Immunopharma Inc. stock price is $0.07, with a previous close of $0.07.
What is Estrella Immunopharma Inc. (ESLAW) current market capitalization?
Estrella Immunopharma Inc. market cap is approximately 2.94 million.
What is Estrella Immunopharma Inc. (ESLAW) EBITDA?
Estrella Immunopharma Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.29 million.
Does Estrella Immunopharma Inc. (ESLAW) pay dividends?
No. Estrella Immunopharma Inc. does not pay a dividend.
What is Estrella Immunopharma Inc. (ESLAW) beta (volatility) score?
Estrella Immunopharma Inc. has a beta of -0.090, indicating lower volatility than the overall market.
